Seattle Genetics, Inc.

NASDAQ: SGEN
$228.74
+$0.00 (+0.0%)
Closing price January 9, 2024

SGEN Chart and Intraday Price

SGEN Company Data

Asset Type ETF
Exchange NASDAQ
Sector Healthcare
Industry Drugs

SGEN Articles

The U.S. Treasury Department and the Federal Reserve took decisive steps to prevent the collapse of two banks from turning into a bank run. Equities were showing some positive effects early Monday.
Warren Buffett's annual letter, Bed Bath & Beyond's latest lease on life and a possible pharma deal worth more than $30 billion.
Friday's top analyst upgrades and downgrades included Activision Blizzard, Analog Devices, Baker Hughes, Coinbase Global, Devon Energy, Electronic Arts, Expedia, Fastly, Marathon Oil, Nvidia, Roku,...
Tuesday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Boeing, Dow, LyondellBasell Industries, Netflix, Splunk, Spotify Technology, T-Mobile, Vale and Walmart.
These five top Goldman Sachs Conviction List stock picks have the largest upside to the firm's target prices. Growth investors concerned about market and economic uncertainty may want to have them in...
Tuesday's top analyst upgrades and downgrades included Cheniere Energy, Disney, Intel, Salesforce, Toyota, and Wynn Resorts.
Two tech stocks that have taken some lumps in recent days received a boost Monday from analyst upgrades.
Tuesday’s top analyst upgrades and downgrades included Alibaba, Amazon.com, Apple, Carvana, Illumina, NextEra Energy, Nikola, Shake Shack, Teladoc Health and WPX Energy.
Tuesday's top analyst upgrades and downgrades included Alphabet, Citigroup, Facebook, Lennar, Netflix, NextEra, Nvidia, Nike, Pinterest, Roku and Snap.
Friday's top analyst upgrades and downgrades included Alexion Pharmaceuticals, Allscripts Healthcare Solutions, Alphabet, Amazon.com, Apple, Baidu, Comcast, Electronic Arts, Ford and Facebook.
We screened the Goldman Sachs Conviction List for the stocks that have the biggest upside to the firm's price targets and found five that look like outstanding ideas for the balance of 2020 and...
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
Friday's top analyst upgrades and downgrades included AGNC Investment, Annaly Capital Management, Arbutus Biopharma, Blackstone, Chevron, Enphase Energy, Exxon Mobil, General Motors, Intel, Tesla and...
Tuesday's top analyst upgrades and downgrades included ANGI Homeservices, Carnival, Chegg, Clorox, Crocs, Dish Network, Etsy, Intercept Pharmaceuticals, Micron Technology, Okta, Seattle Genetics,...
Goldman Sachs analysts are bullish on these four top biotech stocks in front of first-quarter results. None of these companies is a proverbial one-trick pony, and they all are potential takeover...